Optimization of Immunoglobulin Substitution Therapy by a Stochastic Immune Response Model
Open Access
- 28 May 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (5) , e5685
Abstract
The immune system is a complex adaptive system of cells and molecules that are interwoven in a highly organized communication network. Primary immune deficiencies are disorders in which essential parts of the immune system are absent or do not function according to plan. X-linked agammaglobulinemia is a B-lymphocyte maturation disorder in which the production of immunoglobulin is prohibited by a genetic defect. Patients have to be put on life-long immunoglobulin substitution therapy in order to prevent recurrent and persistent opportunistic infections. We formulate an immune response model in terms of stochastic differential equations and perform a systematic analysis of empirical therapy protocols that differ in the treatment frequency. The model accounts for the immunoglobulin reduction by natural degradation and by antigenic consumption, as well as for the periodic immunoglobulin replenishment that gives rise to an inhomogeneous distribution of immunoglobulin specificities in the shape space. Results are obtained from computer simulations and from analytical calculations within the framework of the Fokker-Planck formalism, which enables us to derive closed expressions for undetermined model parameters such as the infection clearance rate. We find that the critical value of the clearance rate, below which a chronic infection develops, is strongly dependent on the strength of fluctuations in the administered immunoglobulin dose per treatment and is an increasing function of the treatment frequency. The comparative analysis of therapy protocols with regard to the treatment frequency yields quantitative predictions of therapeutic relevance, where the choice of the optimal treatment frequency reveals a conflict of competing interests: In order to diminish immunomodulatory effects and to make good economic sense, therapeutic immunoglobulin levels should be kept close to physiological levels, implying high treatment frequencies. However, clearing infections without additional medication is more reliably achieved by substitution therapies with low treatment frequencies. Our immune response model predicts that the compromise solution of immunoglobulin substitution therapy has a treatment frequency in the range from one infusion per week to one infusion per two weeks.Keywords
This publication has 41 references indexed in Scilit:
- Deriving a germinal center lymphocyte migration model from two-photon dataJournal of Experimental Medicine, 2008
- Immunoglobulins: Basic ConsiderationsChemInform, 2007
- Shortage of human intravenous immunoglobulin—reasons and possible solutionsNature Clinical Practice Neurology, 2007
- Inhibition of maturation and function of dendritic cells by intravenous immunoglobulinBlood, 2003
- Statistical model for receptor-ligand binding thermodynamicsPhysical Review E, 2002
- Shortage of Intravenous ImmunoglobulinAnnals of Allergy, Asthma & Immunology, 1998
- Germinal CentersAnnual Review of Immunology, 1994
- Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemiaCell, 1993
- Theoretical studies of clonal selection: Minimal antibody repertoire size and reliability of self-non-self discriminationJournal of Theoretical Biology, 1979
- FLUORESCEIN TEST OF CIRCULATION TIME IN PERIPHERAL VASCULAR DISEASEHeart, 1951